The FDA approved Auvelity (dextromethorphan HBr and bupropion HCl) on April 30, 2026, to treat agitation associated with dementia due to Alzheimer's disease in adults. This is the first FDA-approved treatment for Alzheimer's agitation that isn't an antipsychotic.

For families caring for adults with Down syndrome, this matters. Adults with Down syndrome face a 90% or higher lifetime risk of developing Alzheimer's disease, often in their 40s and 50s, decades earlier than typical onset. About 30% of people with Down syndrome in their 50s and 50% in their 60s develop Alzheimer's dementia. Agitation is one of the most challenging symptoms for families to manage at home.

What Changed

Until this approval, the only FDA-approved medication for Alzheimer's agitation was brexpiprazole (Rexulti), an antipsychotic that carries a boxed warning for increased mortality risk in elderly patients with dementia-related psychosis. Many families and providers have been reluctant to use antipsychotics due to these safety concerns and side effects like sedation, motor problems, and metabolic changes.

Auvelity works differently. It targets NMDA and sigma-1 receptors through its dextromethorphan component. Bupropion blocks an enzyme that breaks down dextromethorphan, keeping levels stable in the bloodstream. The exact mechanism for reducing agitation isn't fully understood, but the drug doesn't work through antipsychotic pathways.

The Evidence

The FDA approval was based on four Phase 3 clinical trials involving adults with Alzheimer's disease and agitation.

In the ACCORD-2 study, patients who continued taking Auvelity had a 3.6-fold lower risk of agitation relapse compared to those switched to placebo. Only 8.4% of people on Auvelity experienced relapse versus 28.6% on placebo.

In the ADVANCE-1 trial, Auvelity showed statistically significant improvement over placebo on the Cohen-Mansfield Agitation Inventory, a standard measure of agitation severity. A second trial, ADVANCE-2, showed numerical improvements but didn't meet its primary endpoint.

Discontinuation rates due to side effects were low and matched placebo. The most common side effects in the agitation trials were dizziness and indigestion.

What This Means for Families Caring for Adults With Down Syndrome

Adults with Down syndrome develop Alzheimer's disease pathology earlier and faster than the general population. Nearly all have brain changes consistent with Alzheimer's by age 40. The progression from pathology to symptoms happens more quickly, and tau protein levels are higher for a given level of amyloid plaques.

Agitation can include verbal outbursts, physical restlessness, repeated questions, resistance to care, and wandering. It disrupts daily routines, strains caregiver relationships, and often triggers emergency room visits or placement changes.

Auvelity offers an alternative to antipsychotics for families who've avoided medication due to safety concerns or for those whose loved ones didn't tolerate or respond to brexpiprazole. It's not a cure for Alzheimer's disease or a treatment for memory loss. It's a targeted intervention for agitation, a specific behavioral symptom.

The clinical trials studied adults with Alzheimer's disease broadly, not specifically people with Down syndrome. However, Alzheimer's disease in people with Down syndrome follows similar pathological processes. Providers familiar with Down syndrome-associated dementia will need to weigh the evidence and make individualized treatment decisions.

What Families Can Do Now

• Talk to your loved one's care provider about whether Auvelity is appropriate. Bring documentation of agitation symptoms, including frequency, duration, and impact on daily life.
• Ask about other contributing factors before starting medication. Agitation can be triggered by untreated pain, infections, medication side effects, or environmental stressors. Rule those out first.
• Request monitoring for side effects if Auvelity is prescribed. The most common are dizziness and indigestion. Your provider should have a plan for follow-up and dosage adjustments.
• Review current medications with your pharmacist. Auvelity interacts with MAO inhibitors, which are contraindicated. Bupropion can lower seizure threshold, so it may not be appropriate for people with a history of seizures.

Where to Find More Information

The National Down Syndrome Society maintains resources on Alzheimer's disease and Down syndrome, including screening tools and care planning guides. The Alzheimer's Association has specific guidance on recognizing dementia symptoms in people with intellectual disabilities, where changes in cognition can be harder to detect against a baseline of developmental disability.

Auvelity was originally approved for major depressive disorder in 2022. The April 2026 approval is an expanded indication for the same formulation. Insurance coverage for the new indication may vary. Contact your insurance company or pharmacy benefits manager to confirm coverage before filling a prescription.

Alzheimer's disease is the leading cause of death in adults with Down syndrome over age 35. For families navigating this diagnosis, a non-antipsychotic treatment option for one of the disease's most disruptive symptoms is a meaningful addition to the limited set of tools currently available.